The malignant tumor is a multi-etiological, systemic and complex disease characterized by
uncontrolled cell proliferation and distant metastasis. Anticancer treatments including …

Metastatic dissemination of solid tumors, a leading cause of cancer-related mortality,
underscores the urgent need for enhanced insights into the molecular and cellular …

Cancer therapies will increasingly be utilized in combination to treat advanced malignancies
so as to increase their long-term efficacy in a greater proportion of patients. In particular …

Drug resistance presents a challenge to the treatment of cancer patients. Many studies have
focused on cell-autonomous mechanisms of drug resistance. By contrast, we proposed that …

The identification of driver oncogenes has provided important targets for drugs that can
change the landscape of cancer therapies. One such example is the BRAF oncogene, which …

The phosphatidylinositol‐3 kinase (PI3K)–AKT pathway is one of the most commonly
dysregulated pathways in all of cancer, with somatic mutations, copy number alterations …

Patients with advanced melanoma have traditionally had very poor prognosis. However,
since 2011 better understanding of the biology and epidemiology of this disease has …

Abstract Background The RTK/PI3K/AKT pathway plays key roles in the development and
progression of many cancers, including GBM. As a regulatory molecule and a potential drug …

This study addresses the role of PTEN loss in intrinsic resistance to the BRAF inhibitor
PLX4720. Immunohistochemical staining of a tissue array covering all stages of melanocytic …

Purpose To assess pharmacodynamic effects and intrinsic and acquired resistance
mechanisms of the BRAF inhibitor vemurafenib in BRAF V600-mutant melanoma, leading to …